Immunotherapy combo shows promise in tough brain cancer trial
NCT ID NCT03197506
First seen Apr 06, 2026 · Last updated Jun 08, 2026 · Updated 9 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 52 adults with this diagnosis will receive the combination therapy. The goal is to see if the treatment is safe and improves survival compared to standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.